Home/Filings/4/0000921895-25-002133

4//SEC Filing

BIOTECHNOLOGY VALUE FUND L P 4

Accession 0000921895-25-002133

CIK 0001633932other

View on SEC.gov Company Profile

Filed

Aug 6, 8:00 PM ET

Accepted

Aug 7, 4:36 PM ET

Size

38.2 KB

Accession

0000921895-25-002133

Insider Transaction Report

Form 4

Period: 2025-08-05

ESSA Pharma Inc.EPIX

BVF PARTNERS L P/IL

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total

BIOTECHNOLOGY VALUE FUND L P

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)

BVF I GP LLC

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)

Biotechnology Value Trading Fund OS LP

Other

Transactions

Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total

BVF Partners OS Ltd.

Other

Transactions

Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total

BVF GP HOLDINGS LLC

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)

BVF INC/IL

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total

LAMPERT MARK N

10% Owner

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)

BIOTECHNOLOGY VALUE FUND II LP

Other

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total

BVF II GP LLC

Other

Transactions

Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,481,634$148→ 6,194,224 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+1,235,030$124→ 4,726,809 total
Exercise of In-Money
Common Stock
2025-08-05$0.00/sh+203,336$20→ 560,808 total
Sale
Common Stock
2025-08-05$1.88/sh−79$148→ 6,194,145 total
Sale
Common Stock
2025-08-05$1.88/sh−66$124→ 4,726,743 total
Sale
Common Stock
2025-08-05$1.88/sh−11$21→ 560,797 total
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,481,634→ 0 total
Exercise: $0.00→ Common Stock (1,481,634 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−1,235,030→ 0 total
Exercise: $0.00→ Common Stock (1,235,030 underlying)
Exercise of In-Money
Pre-funded Warrants
2025-08-05−203,336→ 0 total
Exercise: $0.00→ Common Stock (203,336 underlying)

Footnotes (5)

[F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
[F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
[F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
[F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
[F5]On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares.

Documents

1 file

4
form407422epix_08072025.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

ESSA Pharma Inc.

CIK 0001633932

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0000918923

Filing Metadata

Form type: 4
Filed: Aug 6, 8:00 PM ET
Accepted: Aug 7, 4:36 PM ET
Size: 38.2 KB

View on SEC.gov